Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance

28 Aug 2013

Abstract excerpt

Non-Hodgkin's lymphoma (NHL) is a heterogeneous class of cancers displaying a diverse range of biological phenotypes, clinical behaviours and prognoses. Standard treatments for B-cell NHL are anthracycline-based combinatorial chemotherapy regimens composed of cyclophosphamide, doxorubicin, vincristine and prednisolone. Even though complete response rates of 40-50% with chemotherapy can be attained, a substantial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Lymphoma Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23986223
DOI: 10.1177/1535370213498985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistancePMID 23986223Read ↗

Drug Resistance in Non-Hodgkin LymphomasSemantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.Semantic proximity Read ↗

Multi-drug resistance in B-cell chronic lymphocytic leukemia (B-CLL): A feature of B-CLL sub-sets with poor prognosis genetic alterations?Semantic proximity Read ↗

Genomic landscape of mature B-cell non-Hodgkin lymphomas - an appraisal from lymphomagenesis to drug resistance.Semantic proximity Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

Management of Drug Resistance in Mantle Cell LymphomaSemantic proximity Read ↗

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read ↗

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor ProgressionSemantic proximity Read ↗

Non-Hodgkin lymphoma: diagnosis and treatment.Semantic proximity Read ↗

New targeted therapies for malignant lymphoma based on molecular heterogeneity.Semantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.